Connecticut consolidation finally over for Pfizer

Pfizer says the painful cutting at its R&D operations in Connecticut is finally over. And the budget ax evidently cut a little deeper than expected. The pharma giant told The Day that it now has 3,300 employees at its consolidated headquarters in Groton. Two years ago Pfizer outlined plans to chop 1,100 staffers, mostly scientists, in order to whittle down its R&D budget. That should have left 3,400 staffers. "There are no further planned reductions," Pfizer spokeswoman Lauren Starr tells The Day. "Groton is of central importance to the company." The company has a number of facilities up for sale in the wake of the consolidation. Story


Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.